TABLE 1.

In vitro MICs of doripenem and comparative β-lactams for A. baumannii, 10 species of Enterobacteriaeae, enterococci, staphylococci, and streptococci^a

Organism, antimicrobial agent, and isolate phenotype	No. of isolates tested	MIC (μg/ml)
		Range	Mode	MIC50	MIC90
Acinetobacter baumannii
Aztreonam
Ceftazidime-susceptible	20	8->32	16	32	>32
Ceftazidime-intermediate or resistant	10	16->32	>32	>32	>32
Cefepime
Ceftazidime-susceptible	20	≤0.5-16	4	4	8
Ceftazidime-intermediate or resistant	10	8->32	>32	>32	>32
Ceftriaxone
Ceftazidime-susceptible	20	4-32	16	16	32
Ceftazidime-intermediate or resistant	10	32->64	>64	>64	>64
Doripenem
Ceftazidime-susceptible	20	0.12-1	0.12	0.25	1
Ceftazidime-intermediate or resistant	10	0.25->16	1	1	>16
Ertapenem
Ceftazidime-susceptible	20	0.5-16	2	2	8
Ceftazidime-intermediate or resistant	10	2->16	8	8	>16
Imipenem
Ceftazidime-susceptible	20	0.06-0.5	0.25	0.25	0.25
Ceftazidime-intermediate or resistant	10	0.25->16	1	1	8
Meropenem
Ceftazidime-susceptible	20	0.12-2	0.25	0.25	1
Ceftazidime-intermediate or resistant	10	0.25->16	2	2	16
Piperacillin-tazobactam
Ceftazidime-susceptible	20	≤1-32	≤1	4	32
Ceftazidime-intermediate or resistant	10	32->128	>128	128	>128
Citrobacter freundii
Aztreonam
Ceftazidime-susceptible	21	≤1-8	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	20	4->32	16	16	>32
Cefepime
Ceftazidime-susceptible	21	≤0.5	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	20	≤0.5-16	≤0.5	1	4
Ceftriaxone
Ceftazidime-susceptible	21	≤0.5-2	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	20	8->64	32	32	>64
Doripenem
Ceftazidime-susceptible	21	≤0.015-0.06	0.03	0.03	0.03
Ceftazidime-intermediate or resistant	20	0.03-0.25	0.06	0.06	0.12
Ertapenem
Ceftazidime-susceptible	21	≤0.015-0.03	≤0.015	≤0.015	≤0.015
Ceftazidime-intermediate or resistant	20	0.03-0.5	0.12	0.12	0.5
Imipenem
Ceftazidime-susceptible	21	0.12-1	1	1	1
Ceftazidime-intermediate or resistant	20	0.5-2	0.5	0.5	1
Meropenem
Ceftazidime-susceptible	21	≤0.015-0.03	≤0.015	≤0.015	0.03
Ceftazidime-intermediate or resistant	20	≤0.015-0.12	0.06	0.06	0.06
Piperacillin-tazobactam
Ceftazidime-susceptible	21	≤1-8	≤1	≤1	4
Ceftazidime-intermediate or resistant	20	4->128	128	64	>128/PICK>
Enterobacter aerogenes
Aztreonam
Ceftazidime-susceptible	23	≤1-8	≤1	≤1	2
Ceftazidime-intermediate or resistant	20	8->32	16	16	>32
Cefepime
Ceftazidime-susceptible	23	≤0.5-1	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	20	≤0.5->32	≤0.5	≤0.5	4
Ceftriaxone
Ceftazidime-susceptible	23	≤0.5-4	≤0.5	≤0.5	1
Ceftazidime-intermediate or resistant	20	4->64	32	32	>64
Doripenem
Ceftazidime-susceptible	23	0.03-0.12	0.06	0.06	0.12
Ceftazidime-intermediate or resistant	20	0.06-0.12	0.12	0.12	0.12
Ertapenem
Ceftazidime-susceptible	23	≤0.015-0.25	≤0.015	≤0.015	0.06
Ceftazidime-intermediate or resistant	20	0.06-1	0.12	0.25	0.5
Imipenem
Ceftazidime-susceptible	23	0.5-2	2	2	2
Ceftazidime-intermediate or resistant	20	0.5-2	0.5	0.5	1
Meropenem
Ceftazidime-susceptible	23	≤0.015-0.06	0.03	0.03	0.06
Ceftazidime-intermediate or resistant	20	0.03-0.12	0.06	0.06	0.12
Piperacillin-tazobactam
Ceftazidime-susceptible	23	≤1-32	2	2	4
Ceftazidime-intermediate or resistant	20	16->128	64	64	>128
Enterobacter cloacae
Aztreonam
Ceftazidime-susceptible	23	≤1-8	≤1	≤1	2
Ceftazidime-intermediate or resistant	19	16->32	>32	>32	>32
Cefepime
Ceftazidime-susceptible	23	≤0.5	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	19	≤0.5-16	1	2	8
Ceftriaxone
Ceftazidime-susceptible	23	≤0.5-4	≤0.5	≤0.5	1
Ceftazidime-intermediate or resistant	19	16->64	>64	>64	>64
Doripenem
Ceftazidime-susceptible	23	0.03-0.12	0.03	0.03	0.06
Ceftazidime-intermediate or resistant	19	0.06-0.25	0.12	0.12	0.25
Ertapenem
Ceftazidime-susceptible	23	≤0.015-0.5	≤0.015	≤0.015	0.06
Ceftazidime-intermediate or resistant	19	0.06-1	0.5	0.5	1
Imipenem
Ceftazidime-susceptible	23	0.06-4	0.5	0.5	2
Ceftazidime-intermediate or resistant	19	0.5-2	0.5	0.5	1
Meropenem
Ceftazidime-susceptible	23	≤0.015-0.25	0.03	0.03	0.06
Ceftazidime-intermediate or resistant	19	0.06-0.25	0.06	0.06	0.25
Piperacillin-tazobactam
Ceftazidime-susceptible	23	≤1-16	2	2	8
Ceftazidime-intermediate or resistant	19	8->128	128	128	>128
Escherichia coli
Aztreonam
ESBL-negative	22	≤1-8	≤1	≤1	≤1
ESBL-positive	18	4->32	>32	>32	>32
Cefepime
Ertapenem
ESBL-negative	20	≤0.015-0.25	≤0.015	≤0.015	≤0.015
ESBL-positive	20	≤0.015-0.5	0.12	0.06	0.25
Imipenem
ESBL-negative	20	0.12-1	0.25	0.25	1
ESBL-positive	20	0.06-1	0.5	0.5	1
Meropenem
ESBL-negative	20	≤0.015-0.25	0.03	0.03	0.03
ESBL-positive	20	≤0.015-0.12	0.06	0.03	0.06
Piperacillin-tazobactam
ESBL-negative	20	≤1-8	2	2	4
ESBL-positive	20	4->128	>128	>128	>128
Morganella morganii
Aztreonam
Ceftazidime-susceptible	20	≤1	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	1	2
Cefepime
Ceftazidime-susceptible	20	≤0.5-1	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	1	≤0.5
Ceftriaxone
Ceftazidime-susceptible	20	≤0.5	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	1	≤0.5
Doripenem
Ceftazidime-susceptible	20	0.06-0.5	0.25	0.25	0.5
Ceftazidime-intermediate or resistant	1	0.5
Ertapenem
Ceftazidime-susceptible	20	≤0.015-0.06	≤0.015	≤0.015	0.03
Ceftazidime-intermediate or resistant	1	0.06
Imipenem
Ceftazidime-susceptible	20	0.5-4	4	4	4
Ceftazidime-intermediate or resistant	1	4
Meropenem
Ceftazidime-susceptible	20	0.03-0.25	0.12	0.06	0.12
Ceftazidime-intermediate or resistant	1	0.12
Piperacillin-tazobactam
Ceftazidime-susceptible	20	≤1-4	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	1	32
Proteus mirabilis
Aztreonam
Ceftazidime-susceptible	22	≤1->32	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	19	≤1->32	>32	>32	>32
Cefepime
Ceftazidime-susceptible	22	≤0.5	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	19	≤0.5->32	>32	>32	>32
Ceftriaxone
Ceftazidime-susceptible	22	≤0.5	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	19	≤0.5->64	≤0.5	8	64
Doripenem
Ceftazidime-susceptible	22	0.12-2	0.25	0.5	1
Ceftazidime-intermediate or resistant	19	0.25-2	1	1	2
Ertapenem
Ceftazidime-susceptible	22	≤0.015-0.25	≤0.015	≤0.015	0.06
Ceftazidime-intermediate or resistant	19	≤0.015-0.5	0.06	0.06	0.5
Imipenem
Ceftazidime-susceptible	22	1-4	4	4	4
Ceftazidime-intermediate or resistant	19	4-8	4	4	8
Meropenem
Ceftazidime-susceptible	22	0.03-0.25	0.06	0.06	0.25
Ceftazidime-intermediate or resistant	19	0.06-0.25	0.12	0.12	0.25
Piperacillin-tazobactam
Ceftazidime-susceptible	22	≤1-2	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	19	≤1-4	≤1	≤1	2
Providencia spp.
Aztreonam
Ceftazidime-susceptible	20	≤1-2	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	3	≤1-16
Cefepime
Ceftazidime-susceptible	20	≤0.5-2	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	3	≤0.5-2
Ceftriaxone
Ceftazidime-susceptible	20	≤0.5-2	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	3	≤0.5-8
Doripenem
Ceftazidime-susceptible	20	0.12-0.5	0.25	0.25	0.5
Ceftazidime-intermediate or resistant	3	0.25
Ertapenem
Ceftazidime-susceptible	20	≤0.015-0.12	≤0.015	≤0.015	0.06
Ceftazidime-intermediate or resistant	3	≤0.015-0.03
Imipenem
Ceftazidime-susceptible	20	0.5-4	2	2	2
Ceftazidime-intermediate or resistant	3	1-4
Meropenem
Ceftazidime-susceptible	20	0.03-0.12	0.06	0.06	0.12
Ceftazidime-intermediate or resistant	3	0.06-0.12
Piperacillin-tazobactam
Ceftazidime-susceptible	20	≤1-16	≤1	≤1	4
Ceftazidime-intermediate or resistant	3	2-8
Serratia marcescens
Aztreonam
Ceftazidime-susceptible	21	≤1->32	≤1	≤1	≤1
Ceftazidime-intermediate or resistant	19	2->32	>32	>32	>32
Cefepime
Ceftazidime-susceptible	21	≤0.5-2	≤0.5	≤0.5	≤0.5
Ceftazidime-intermediate or resistant	19	1->32	32	8	>32
Ceftriaxone
Ceftazidime-susceptible	21	≤0.5-64	≤0.5	≤0.5	2
Ceftazidime-intermediate or resistant	19	4->64	>64	>64	>64
Doripenem
Ceftazidime-susceptible	21	0.06-0.5	0.12	0.12	0.25
Ceftazidime-intermediate or resistant	19	0.12-0.25	0.12	0.12	0.25
Ertapenem
Ceftazidime-susceptible	21	≤0.015-0.25	≤0.015	0.03	0.12
Ceftazidime-intermediate or resistant	19	≤0.015-0.5	0.12	0.12	0.5
Imipenem
Ceftazidime-susceptible	21	0.25-4	1	1	2
Ceftazidime-intermediate or resistant	19	0.5-4	1	1	2
Meropenem
Ceftazidime-susceptible	21	0.03-0.12	0.06	0.06	0.06
Ceftazidime-intermediate or resistant	19	0.03-0.12	0.06	0.06	0.12
Piperacillin-tazobactam
Ceftazidime-susceptible	21	≤1-16	2	2	4
Ceftazidime-intermediate or resistant	19	4->128	>128	16	>128
Enterococcus faecalis
Cefepime
Vancomycin-susceptible	11	32->32	>32	>32	>32
Vancomycin-intermediate	2	>32
Vancomycin-resistant	7	32->32
Ceftriaxone
Vancomycin-susceptible	11	>64	>64	>64	>64
Vancomycin-intermediate	2	>64
Vancomycin-resistant	7	>64
Doripenem
Vancomycin-susceptible	11	1-8	8	4	8
Vancomycin-intermediate	2	4
Vancomycin-resistant	7	2-8
Ertapenem
Vancomycin-susceptible	11	4-32	8	8	16
Vancomycin-intermediate	2	8-16
Vancomycin-resistant	7	4-32
Imipenem
Vancomycin-susceptible	11	1-2	1	1	2
Vancomycin-intermediate	2	1-2
Vancomycin-resistant	7	1-4
Meropenem
Vancomycin-susceptible	11	2-32	8	8	16
Vancomycin-intermediate	2	8
Vancomycin-resistant	7	2-16
Piperacillin-tazobactam
Vancomycin-susceptible	11	2-4	4	4	4
Vancomycin-intermediate	2	2
Vancomycin-resistant	7	≤1-4
Enterococcus faecium
Cefepime
Vancomycin-susceptible	10	>32	>32	>32	>32
Vancomycin-resistant	11	>32	>32	>32	>32
Ceftriaxone
Vancomycin-susceptible	10	16->64	>64	>64	>64
Vancomycin-resistant	11	>64	>64	>64	>64
Doripenem
Vancomycin-susceptible	10	2->32	>32	32	>32
Vancomycin-resistant	11	>32	>32	>32	>32
Ertapenem
Vancomycin-susceptible	10	16->32	>32	>32	>32
Vancomycin-resistant	11	>32	>32	>32	>32
Imipenem
Vancomycin-susceptible	10	2->32	>32	16	>32
Vancomycin-resistant	11	>32	>32	>32	>32
Meropenem
Vancomycin-susceptible	10	4->32	>32	>32	>32
Vancomycin-resistant	11	>32	>32	>32	>32
Piperacillin-tazobactam
Vancomycin-susceptible	10	4->64	>64	>64	>64
Vancomycin-resistant	11	64->64	>64	>64	>64
Staphylococcus aureus
Cefepime
Oxacillin-susceptible	42	2-4	2	2	4
Oxacillin-resistant	23	8->32	>32	>32	>32
Ceftriaxone
Oxacillin-susceptible	42	≤1-4	2	2	4
Oxacillin-resistant	23	16->64	>64	>64	>64
Doripenem
Oxacillin-susceptible	42	≤0.015-0.06	0.03	0.03	0.06
Oxacillin-resistant	23	0.25->32	32	4	32
Ertapenem
Oxacillin-susceptible	42	0.06-0.25	0.12	0.12	0.25
Oxacillin-resistant	23	0.5->32	>32	8	>32
Imipenem
Oxacillin-susceptible	42	≤0.015-0.03	0.03	≤0.015	0.03
Oxacillin-resistant	23	0.06->32	>32	1	>32
Meropenem
Oxacillin-susceptible	42	0.03-0.25	0.06	0.06	0.12
Oxacillin-resistant	23	0.5->32	>32	4	>32
Piperacillin-tazobactam
Oxacillin-susceptible	42	≤1-2	≤1	≤1	2
Oxacillin-resistant	23	4->64	>64	32	>64
Staphylococcus epidermidis
Cefepime
Oxacillin-susceptible	39	≤1	≤1	≤1	≤1
Oxacillin-resistant	17	≤1-16	4	4	16
Ceftriaxone
Oxacillin-susceptible	39	≤1-2	≤1	≤1	2
Oxacillin-resistant	17	2-32	4	4	32
Doripenem
Oxacillin-susceptible	39	≤0.015-0.06	0.03	0.03	0.03
Oxacillin-resistant	17	≤0.015-4	0.5	1	4
Ertapenem
Oxacillin-susceptible	39	0.12-0.5	0.25	0.25	0.25
Oxacillin-resistant	17	0.25-32	2	2	16
Imipenem
Oxacillin-susceptible	39	≤0.015	≤0.015	≤0.015	≤0.015
Oxacillin-resistant	17	0.03-4	0.06	0.12	2
Meropenem
Oxacillin-susceptible	39	0.03-0.12	0.06	0.06	0.06
Oxacillin-resistant	17	0.06-16	1	1	8
Piperacillin-tazobactam
Oxacillin-susceptible	39	≤1	≤1	≤1	≤1
Oxacillin-resistant	17	≤1-4	≤1	≤1	4
Coagulase-negative staphylococci (non-S. epidermidis)
Cefepime
Oxacillin-susceptible	38	≤1-4	≤1	≤1	2
Oxacillin-resistant	24	≤1->32	2	4	>32
Ceftriaxone
Oxacillin-susceptible	38	≤1-16	≤1	2	4
Oxacillin-resistant	24	2->64	2	8	>64
Doripenem
Oxacillin-susceptible	38	≤0.015-0.5	0.03	0.03	0.12
Oxacillin-resistant	24	0.03-32	0.06	0.5	16
Ertapenem
Oxacillin-susceptible	38	0.06-2	0.25	0.25	0.5
Oxacillin-resistant	24	0.12->32	>32	2	>32
Imipenem
Oxacillin-susceptible	38	≤0.015-0.06	≤0.015	≤0.015	0.03
Oxacillin-resistant	24	≤0.015-32	0.03	0.06	8
Meropenem
Oxacillin-susceptible	38	≤0.015-1	0.06	0.06	0.25
Oxacillin-resistant	24	0.06->32	0.5	1	32
Piperacillin-tazobactam
Oxacillin-susceptible	38	≤1-2	≤1	≤1	≤1
Oxacillin-resistant	24	≤1->64	≤1	2	64
Streptococcus pyogenes
Penicillin
Macrolide-susceptible	10	≤0.06	≤0.06	≤0.06	≤0.06
Cefepime
Macrolide-susceptible	10	≤0.06	≤0.06	≤0.06	≤0.06
Ceftriaxone
Macrolide-susceptible	10	≤0.03	≤0.03	≤0.03	≤0.03
Doripenem
Macrolide-susceptible	10	≤0.008	≤0.008	≤0.008	≤0.008
Ertapenem
Macrolide-susceptible	10	≤0.008-0.015	≤0.008	≤0.008	≤0.008
Imipenem
Macrolide-susceptible	10	≤0.008	≤0.008	≤0.008	≤0.008
Meropenem
Macrolide-susceptible	10	≤0.008	≤0.008	≤0.008	≤0.008
Piperacillin-tazobactam
Macrolide-susceptible	10	≤0.06	≤0.06	≤0.06	≤0.06
Streptococcus agalactiae
Penicillin
Macrolide-susceptible	20	≤0.06	≤0.06	≤0.06	≤0.06
Macrolide-resistant	20	≤0.06	≤0.06	≤0.06	≤0.06
Cefepime
Macrolide-susceptible	20	≤0.06-0.12	≤0.06	≤0.06	≤0.06
Macrolide-resistant	20	≤0.06-0.12	≤0.06	≤0.06	0.12
Ceftriaxone
Macrolide-susceptible	20	≤0.03-0.06	0.06	0.06	0.06
Macrolide-resistant	20	≤0.03-0.12	0.06	0.06	0.06
Doripenem
Macrolide-susceptible	20	≤0.008-0.015	0.015	0.015	0.015
Macrolide-resistant	20	0.015-0.03	0.015	0.015	0.015
Ertapenem
Macrolide-susceptible	20	0.03-0.06	0.03	0.03	0.06
Macrolide-resistant	20	0.03-0.06	0.06	0.06	0.06
Imipenem
Macrolide-susceptible	20	≤0.008-0.015	0.015	0.015	0.015
Macrolide-resistant	20	≤0.008-0.03	0.015	0.015	0.015
Meropenem
Macrolide-susceptible	20	0.03	0.03	0.03	0.03
Macrolide-resistant	20	0.03-0.06	0.03	0.03	0.06
Piperacillin-tazobactam
Macrolide-susceptible	20	0.25-0.5	0.25	0.25	0.25
Macrolide-resistant	20	0.25-0.5	0.25	0.25	0.5
Streptococcus pneumoniae
Cefepime
Penicillin-susceptible	44	≤0.06	≤0.06	≤0.06	≤0.06
Penicillin-intermediate	23	≤0.06-1	0.5	0.25	1
Penicillin-resistant	33	0.5-4	1	1	2
Ceftriaxone
Penicillin-susceptible	44	≤0.03	≤0.03	≤0.03	≤0.03
Penicillin-intermediate	23	≤0.03-0.5	0.5	0.25	0.5
Penicillin-resistant	33	0.5-8	1	1	4
Doripenem
Penicillin-susceptible	44	≤0.008-0.015	≤0.008	≤0.008	≤0.008
Penicillin-intermediate	23	0.015-0.5	0.25	0.12	0.25
Penicillin-resistant	33	0.25-1	1	0.5	1
Ertapenem
Penicillin-susceptible	44	≤0.008-0.03	0.015	0.015	0.015
Penicillin-intermediate	23	0.03-1	0.03	0.25	1
Penicillin-resistant	33	0.5-4	0.5	1	2
Imipenem
Penicillin-susceptible	44	≤0.008-0.015	≤0.008	≤0.008	≤0.008
Penicillin-intermediate	23	≤0.008-0.25	0.12	0.06	0.12
Penicillin-resistant	33	0.12-1	0.5	0.5	1
Meropenem
Penicillin-susceptible	44	≤0.008-0.03	≤0.008	≤0.008	≤0.008
Penicillin-intermediate	23	0.015-0.5	0.25	0.12	0.5
Penicillin-resistant	33	0.25-2	0.5	0.5	1
Piperacillin-tazobactam
Penicillin-susceptible	44	≤0.06-0.12	≤0.06	≤0.06	≤0.06
Penicillin-intermediate	23	≤0.06-4	2	1	4
Penicillin-resistant	33	2->8	4	4	8
Viridans group streptococci
Cefepime
Penicillin-susceptible	38	≤0.06-0.5	≤0.06	0.12	0.5
Penicillin-intermediate	4	0.25-1
Penicillin-resistant	18	0.5->4	2	2	>4
Ceftriaxone
Penicillin-susceptible	38	≤0.03-0.5	0.06	0.06	0.25
Penicillin-intermediate	4	0.25-1
Penicillin-resistant	18	1->8	4	4	4
Doripenem
Penicillin-susceptible	38	≤0.008-0.06	0.03	0.03	0.06
Penicillin-intermediate	4	0.03-1
Penicillin-resistant	18	0.25-4	1	1	4
Ertapenem
Penicillin-susceptible	38	0.03-0.5	0.06	0.06	0.25
Penicillin-intermediate	4	0.12-2
Penicillin-resistant	18	1->8	4	4	8
Imipenem
Penicillin-susceptible	38	≤0.008-0.06	0.015	0.015	0.06
Penicillin-intermediate	4	0.03-1
Penicillin-resistant	18	0.12-4	2	2	2
Meropenem
Penicillin-susceptible	38	≤0.008-0.12	0.03	0.03	0.06
Penicillin-intermediate	4	0.06-1
Penicillin-resistant	18	0.25-4	2	2	4
Piperacillin-tazobactam
Penicillin-susceptible	38	≤0.06-2	0.12	0.12	1
Penicillin-intermediate	4	0.25-8
Penicillin-resistant	18	0.5->8	>8	8	>8

^aMIC₅₀, the MIC at which 50% of the isolates are inhibited by an antimicrobial agent. The mode, MIC₅₀, and MIC₉₀ were not calculated for phenotype groups of <10 isolates.